Navigation Links
Micromet Closes $80.5 Million Public Offering of Common Stock
Date:3/17/2010

BETHESDA, Md., March 17 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 1.5 million shares of common stock. As a result, Micromet sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 per share.

The Company received net proceeds from the offering of approximately $75.3 million, after deducting the underwriting discount and estimated offering expenses.  The Company plans to use the net proceeds from the financing primarily for general corporate purposes, which may include research and development, capital expenditures, working capital and general and administrative expenses.

Goldman, Sachs & Co. acted as sole book-running manager for this offering. Piper Jaffray & Co., RBC Capital Markets Corporation, Needham & Company, LLC, ROTH Capital Partners, LLC, Ladenburg Thalmann & Co. Inc., and Maxim Group LLC acted as co- managers. A copy of the final prospectus for this offering may be obtained from Goldman, Sachs & Co., Attn: Prospectus Department, 85 Broad Street, New York, New York 10004,
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Announces Proposed Public Offering of Common Stock
2. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
3. Final Data from Phase 2 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
4. Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
5. Micromet to Present at The 8th Annual BIO Investor Forum Conference on October 29, 2009
6. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
7. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
8. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
9. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
10. Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
11. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... LINCOLNSHIRE, Ill. , May 5, 2015 /PRNewswire/ ... medical diagnostic testing equipment and information systems technology, ... laboratory information systems company. This partnership allows Sysmex ... software and interfacing solution for physician offices and ... analyzer directly to Electronic Medical Record (EMR) systems. ...
(Date:5/5/2015)... 2015 GW Pharmaceuticals plc (Nasdaq: GWPH, ... company focused on discovering, developing and commercializing novel ... today the closing of the previously announced offering ... 1,600,000 American Depositary Shares (ADSs) at a price ... approximately $179.2 million (before deducting underwriting discount, commissions ...
(Date:5/5/2015)...  IBM Watson Health (NYSE: IBM ) today ... dozen leading cancer institutes to accelerate the ability of ... patients. The institutes will apply Watson,s ... minutes the ability to translate DNA insights, understand a ... literature to personalize treatment options. The project is part ...
Breaking Medicine Technology:Sysmex America, Inc. Partners with Medicus Middleware to Provide Physician Office Labs with Instrument Connectivity Directly to EMR 2Sysmex America, Inc. Partners with Medicus Middleware to Provide Physician Office Labs with Instrument Connectivity Directly to EMR 3GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 2GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 3GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 4Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 2Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 3Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 4Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 5Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 6
... 2011 The Food and Drug Administration,s international program ... on the new food safety law, as foreign companies ... learn how the law affects them. (Logo: ... became law in January, has been translated into 11 ...
... KALONA, Iowa, Sept. 29, 2011 ... has been installed at the Instituto Radioterapia del Este ... efficient workflow, the Protura system elevates the level of ... eliminates the need for many patients to travel for ...
Cached Medicine Technology:FDA CONSUMER HEALTH INFORMATION -- Foreign Exporters Study Food Safety Law 2CIVCO's Protura™ Installed at Puerto Rico's Instituto Radioterapia del Este 2CIVCO's Protura™ Installed at Puerto Rico's Instituto Radioterapia del Este 3
(Date:5/5/2015)... May 05, 2015 NCPDP announced today ... Program. The program establishes a three-year commitment of strategic ... of 10 Elite Partners. “AmerisourceBergen has supported our multi-stakeholder ... of NCPDP, “and this is a wonderful continuation and ... We can trace AmerisourceBergen back to our very first ...
(Date:5/5/2015)... DC (PRWEB) May 05, 2015 ... Optimity) will present at the 24th ... at 1:15 p.m. MT in Scottsdale, AZ. WEDI, ... nation’s leading nonprofit authority on the use of ... exchange. Donald Graf, National Director of Telemedicine for ...
(Date:5/5/2015)... May 05, 2015 Viverae®, a ... Bard Inc., a leading multinational developer, manufacturer and ... fields of vascular, urology, oncology and surgical specialty ... Award. The Vanguard Award recognizes outstanding achievement ... programs among Viverae’s significant client base. , Viverae ...
(Date:5/5/2015)... Los Angeles, CA (PRWEB) May 05, 2015 ... to treat and actually prevent a variety of health ... Doc utilized this modern research to adopt clean eating ... preservatives and artificial dyes associated with over-consumption of fast ... eating diet plans easy to follow and report ...
(Date:5/5/2015)... TX (PRWEB) May 05, 2015 MAP ... programs and revenue cycle management for addiction treatment facilities, ... as Vice President of Business Development. Mr. Mooney, who ... addiction treatment field, will be responsible for developing new ... distribution of MAP’s core products and new initiatives. , ...
Breaking Medicine News(10 mins):Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 3Health News:Optimity Advisors’ Hiliary Critchley, Telemedicine Expert, to Speak at WEDI Conference May 20th in Scottsdale, AZ 2Health News:Viverae® Honors C. R. Bard, Inc. with 2015 Vanguard Award 2Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 2Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 3Health News:Jimmy Mooney, an Addiction Treatment Veteran, Named Vice President of Business Development at MAP Health Management, LLC 2
... proportions”, a study finding which says that hormone replacement therapy ... of heart disease. , The study published in ... replacement therapy or HRT, taken by women in their 50’s ... attacks and other such conditions. , This finding ...
... cancer patients in the U.S. fails to receive the ... study of hospital data from nine states found that ... Hispanic race, or insured by Medicaid, were at greatest ... oncologists, by surgeons who perform few ovarian cancer surgeries, ...
... land. But there too strident voices are being raised in ... to ensure availability of lower-cost copies of biotechnology drugs that ... year. ,Generics are now allowed only for traditional, ... for complex biological drugs such as hormones or antibodies used ...
... hospitals in Mumbai will soon start an integrated trauma ... and trauma care //to patients on way to a ... powerful American Association of Physicians of Indian Origin (AAPI), ... citizens to avail fully equipped ambulances within minutes of ...
... at the Johns Hopkins Urology Robotics Lab report the ... can safely power remote-controlled // robotic medical devices used ... imaging. The motor that drives the devices can be ... and more precise than a human hand. ,"Lots ...
... food industry is estimated to be worth over $200 million and ... Confederation of Indian Industry (CII). ,The growth of the ... the already booming food retail industry, which is currently growing at ... discussed in a two-day international food meet to be held in ...
Cached Medicine News:Health News:Hormone Replacement Therapy- Not A Fallen Angel 2Health News:Many Women Undertreated for Ovarian Cancer 2Health News:Law Emerging in US for Generic Versions of Biotech Medicine 2Health News:Law Emerging in US for Generic Versions of Biotech Medicine 3Health News:Integrated Trauma Care Facility in Mumbai 2Health News:Integrated Trauma Care Facility in Mumbai 3Health News:MRI Robotic Biopsies Simplified by PneuStep 2
...
The Tew cranial/spinal retractor is designed for posterior fossa or intraspinal microsurgery where retraction is required. Clinical applications are: Posterior fossa microsurgery and intraspinal micr...
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
The Budde Halo brain retractor is designed for use in all intercranial procedures where retraction of delicate brain tissue is required....
Medicine Products: